远程卒中指导下的静脉组织型纤溶酶原激活物治疗在综合性卒中中心可获得与溶栓相似的临床结局。
Telestroke-guided intravenous tissue-type plasminogen activator treatment achieves a similar clinical outcome as thrombolysis at a comprehensive stroke center.
机构信息
University of Pittsburgh Medical Center Stroke Institute, Pittsburgh, PA, USA.
出版信息
Stroke. 2011 Nov;42(11):3291-3. doi: 10.1161/STROKEAHA.111.625046. Epub 2011 Sep 1.
BACKGROUND AND PURPOSE
Telestroke networks offer an opportunity to increase tissue-type plasminogen activator use in community hospitals.
METHODS
We compared 83 patients treated with intravenous tissue-type plasminogen activator by telestroke to 59 patients treated after in-person evaluation by the same neurologists at a tertiary care stroke center. Onset and door-to-treatment times and functional outcome at 90 days were obtained prospectively. Favorable outcome was defined as modified Rankin Scale score ≤2.
RESULTS
Favorable outcome rates were comparable between the groups (42.1% versus 37.5%, P=0.7). There was no significant difference in the rate of symptomatic hemorrhage.
CONCLUSIONS
Telestroke is a viable alternative to in-person evaluation when stroke expertise is not readily available.
背景与目的
远程卒中网络为增加社区医院使用组织型纤溶酶原激活物提供了机会。
方法
我们比较了 83 例通过远程卒中接受静脉内组织型纤溶酶原激活物治疗的患者和 59 例在三级卒中中心由同一位神经科医生进行现场评估后接受治疗的患者。前瞻性地获得发病至治疗时间和 90 天的功能结局。良好结局定义为改良 Rankin 量表评分≤2。
结果
两组的良好结局率相当（42.1%与 37.5%，P=0.7）。症状性出血率无显著差异。
结论
当卒中专业知识不易获得时，远程卒中是现场评估的可行替代方法。
Zotero 插件